Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01756898 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 370
- Enrollment target
NCT01756898 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 370 participants.
The verdict
NCT01756898, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 370 participants
- Enrollment target
Study Summary
The purpose of this research study is to gather scientific information about the effectiveness of the study drug, ASB17061 capsules, when compared to placebo in adult subjects with atopic dermatitis.
Interventions
- DRUG Placebo
- DRUG 5 mg ASB17061
- DRUG 10 mg ASB17061
- DRUG 20 mg ASB17061
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2012-11-28 |
| Est. Completion | 2014-01-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01756898
The ClinicalTrials.gov registry entry for NCT01756898 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01756898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01756898 about?
NCT01756898 is a clinical study titled "Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis". The purpose of this research study is to gather scientific information about the effectiveness of the study drug, ASB17061 capsules, when compared to placebo in adult subjects with atopic dermatitis.
What is the current status of trial NCT01756898?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 370 participants. The study started on 2012-11-28. Estimated completion is 2014-01-14.
What interventions are being tested in trial NCT01756898?
The interventions under investigation include: Placebo (DRUG), 5 mg ASB17061 (DRUG), 10 mg ASB17061 (DRUG), 20 mg ASB17061 (DRUG).
Who is sponsoring clinical trial NCT01756898?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.